At the 2019 AACC in Anaheim, CA, Booth #4339, Credo Diagnostics launched our VitaPCR™ Instrument and our first VitaPCR™ Influenza A&B Assay.
After one year, our product lines include the VitaPCR™ SARS-CoV-2 Gen 2 Assay, VitaPCR™ Influenza/SARS-CoV-2 Assay, VitaPCR™ Influenza/RSV Assay, and VitaPCR™ Strep A Assay.
For AACC 2022 in Chicago, Credo Diagnostics are happy to announce our participation, and importantly, will introduce our new molecular diagnostic platform – VitaSIRO solo™, and share what we have done since the onset of COVID-19 to help countries provide VitaPCR™ machines.
“Today, it is a great honour to see our solutions accepted and requested by users worldwide. We strive to provide the best solutions to our customers continually and we will never stop innovating.”
Come visit us at Booth #4456 to see for yourself.
Credo Diagnostics, “Advanced Medical Technology For All”
